In 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of a dual (Inhaled corticosteroid/ Formoterol) combination treatment to be used as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an a

Biologics are a class of medications that are specifically designed to target and modify specific components

As many as one-in-two healthcare attendances for breathing difficulties in Bradford could be triggered by breaches in daily air pollution limits, new research has uncovered. 

A new report is showcasing the impact of a national AHSN Network programme to improve access to FeNO testing for asthma diagnosis. Fractional exhaled Nitric Oxide (FeNO) tests are simple, non-invasive tests to support the diagnosis of asthma.

A new report is showcasing the impact of a national AHSN Network programme to improve access to FeNO testing for asthma diagnosis.

Viv Marsh (Asthma Nurse Specialist) is joined by Amanda Roberts (PCRS Patient Reference Group and PCRS Education Committee Patient Representative) to discuss all things Asthma Action Plans in this episode of the PCRS Podcast.

The PCRS Patient Reference Group (PRG) is a small group of people with respiratory conditions who support PCRS to ensure that we always try to embed the patient perspective in our work and consider the holistic management of patients.

This pragmatic guide focuses on the ongoing management of adults and children with severe asthma receiving biologic therapy and has been developed by an expert group led by Will Carroll, University Hospital of the North Midlands, Stoke-on-Trent and including Ernie Wong, Imperial College Healthcar

In an ideal world, asthma review appointments will be between 20 to 30 minutes in duration. But we are not living in an ideal world.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has for the first time approved the use of a dual (ICS/beta-agonist) combination treatment to be prescribed as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an

To consider how and when we use FeNO testing, we need to go to the definition of asthma. Both BTS/SIGN1 and GINA2 define it as a predominantly inflammatory disorder of the airways with airway hyperresponsiveness and variability in symptoms.

Asthma is a long-term condition characterised for the vast majority by trigger induced eosinophilic airway inflammation resulting in wheeze, breathlessness, cough, and chest tightness.

In this PCRS Podcast episode, Carol Stonham (Primary Care Nurse and PCRS Policy Lead) is in conversation with Amanda Roberts (PCRS Patient Reference Group and PCRS Education Committee Patient Representative) to delve into the positive and negative aspects of Amanda's asthma reviews of the past, d

This spring, Primary Care Respiratory Update comes to you with a new focus on asthma.

March 2023 saw the first approval of a combination inhaled corticosteroid + long-acting beta2-agonist inhaler for the management of mild asthma in people over 12 years of age. The approval supports the move away from reliance on short-acting beta2-agonists which fa